Annexon, Inc. - 8-K Filing
Annexon reported first-quarter 2026 financial results with $225 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing a runway into the second half of 2027. R&D expenses were $35.8 million for the quarter, down from $48.2 million in the same period in 2025, while G&A expenses were $10.3 million, up from $9.2 million. The company incurred a net loss of $44.1 million, or $0.23 per share, compared to $54.4 million, or $0.37 per share, in the prior-year quarter. Key upcoming milestones include topline data from the Phase 3 ARCHER II trial for vonaprument in... (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ANNX